OnKure Therapeutics, Inc. — Director's Dealing 2021

Aug 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-08-25

Reporting Person: Jindal Vineet R. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-25	Common Stock	P	5000	$7.4353	Acquired	5000	Direct

Footnotes

F1: The weighted average purchase price for the transaction was $7.4353. The shares were purchased at a range of prices between $7.39 and $7.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.